<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879434</url>
  </required_header>
  <id_info>
    <org_study_id>OSTCMC-PMCF-DE-2018-01</org_study_id>
    <nct_id>NCT03879434</nct_id>
  </id_info>
  <brief_title>Routine Application of Ostenil® Mini in Patients With Rhizarthrosis</brief_title>
  <official_title>Routine Application of Ostenil® Mini in Patients With Rhizarthrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRB Chemedica AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TRB Chemedica AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PMCF study to observe the routine application of Ostenil® Mini in the treatment of pain and&#xD;
      restricted mobility in degenerative and traumatic changes of the CMC joint.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2019</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Pain Intensity compared to Baseline (VAS-slider)</measure>
    <time_frame>Day 7, Day 14, Day 84 after last injection, Day 168 after last injection</time_frame>
    <description>Evaluation of Pain Intensity by the Patient on a 10 cm VAS-slider. (10 cm equal the worst pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Subjective Therapy Evaluation (FIHOA Questionnaire, 4 grade scale) compared to Baseline</measure>
    <time_frame>Day 7, Day 14, Day 84 after last injection, Day 168 after last injection</time_frame>
    <description>Functional Index for Hand OsteoArthritis (FIHOA) to assess hand-OA related functional impairment on a 4-grade scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Subjective Quality of Life Evaluation (Questionnaire with 5 Point Likert scale) compared to Baseline</measure>
    <time_frame>Day 7, Day 14, Day 84 after last injection, Day 168 after last injection</time_frame>
    <description>Questionnaire to assess hand-OA related Quality of Life on a 5-grade scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Subjective Symptom Evaluation (Overall Impression on a scale from 1 to 5)</measure>
    <time_frame>Day 7, Day 14, Day 84 after last injection, Day 168 after last injection</time_frame>
    <description>The Change of Overall Subjective Symptom Evaluation on a scale from 1 (much improved) to 5 (much worse)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to Day 252 after the last injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Key Pinch Strength compared to Baseline (Pinch Gauge)</measure>
    <time_frame>Day 7, Day 14, Day 84 after last injection, Day 168 after last injection</time_frame>
    <description>Measurement of Key Pinch in kilograms with a Pinch Gauge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Tip Pinch Strength compared to Baseline (Pinch Gauge)</measure>
    <time_frame>Day 7, Day 14, Day 84 after last injection, Day 168 after last injection</time_frame>
    <description>Measurement of Tip Pinch in kilograms with a Pinch Gauge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Palmar Pinch Strength compared to Baseline (Pinch Gauge)</measure>
    <time_frame>Day 7, Day 14, Day 84 after last injection, Day 168 after last injection</time_frame>
    <description>Measurement of Palmar Pinch in kilograms with a Pinch Gauge</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Rhizarthrosis</condition>
  <arm_group>
    <arm_group_label>Ostenil® Mini</arm_group_label>
    <description>1-3 injections of sodium hyaluronate 1.0 % (10 milligrams (mg) / 1,0 millilitres (ml)) in weekly interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ostenil® Mini</intervention_name>
    <description>Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation</description>
    <arm_group_label>Ostenil® Mini</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult Patients with Rhizarthrosis and a Recommendation for Treatment with Ostenil® Mini.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects ≥ 18 years of age and in good general health condition&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Existing Ostenil® Mini recommendation for the treatment of rhizarthrosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to one of the Ostenil® Mini components&#xD;
&#xD;
          -  Known pregnancy or lactating females&#xD;
&#xD;
          -  Presence of coagulation disorder&#xD;
&#xD;
          -  Subjects not capable of contracting and of understanding the nature, risks,&#xD;
             significance and implications of the clinical investigation and unable to form a&#xD;
             rational intention in the light of these facts&#xD;
&#xD;
          -  Subjects unable to understand informed consent or having a high probability of non&#xD;
             compliance to the study procedures and / or non completion of the study according to&#xD;
             investigator's judgement (e.g. illiteracy, insufficient knowledge of local language)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raphaela Geiger</last_name>
    <phone>+49 89 461483-27</phone>
    <email>geiger@trbchemedica.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucia Hopp</last_name>
    <phone>+49 89 461483-29</phone>
    <email>hopp@trbchemedica.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Praxis für Orthopädie und Unfallchirurgie</name>
      <address>
        <city>Berlin</city>
        <zip>10711</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Hüske, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orthopädie am Tauentzien</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Reiche, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Berlin Freiheit 1</name>
      <address>
        <city>Berlin</city>
        <zip>12555</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Orthopädie am Kiesteich</name>
      <address>
        <city>Berlin</city>
        <zip>13589</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaf Neubert, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wirbelsäulen Gelenk Zentrum Westend</name>
      <address>
        <city>Berlin</city>
        <zip>14052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

